Univariate analysis of cumulative incidence of clinically significant (II-IV and III-IV) acute GVHD in association with HPSE gene SNP combinations and their discrepancy according to the conditioning regimen
| Grade . | Conditioning regimen . | SNP combinations/ group of discrepancy . | Cumulative incidence, % . | 95% CI for cumulative incidence . | χ2/P . |
|---|---|---|---|---|---|
| II-IV | RIC, fludarabine/high-dose busulfan, fludarabine/treosulfan | HR | 36.5 | 24.0-55.5 | 6.5/.039 |
| MR | 34.8 | 25.4-47.9 | |||
| LR | 17.1 | 9.7-30.1 | |||
| III-IV | HR | 23.2 | 12.6-42.8 | 4.9/.08 | |
| MR | 16.2 | 9.1-28.7 | |||
| LR | 7.3 | 2.8-18.9 | |||
| II-IV | Myeloablative, fludarabine/melphalan | HR | 69.7 | 57.5-84.7 | 12.5/.002 |
| MR | 46.1 | 35.8-59.2 | |||
| LR | 34.7 | 23.1-52.3 | |||
| III-IV | HR | 59.5 | 45.9-77.3 | 17.3/< .001 | |
| MR | 27.7 | 18.3-41.7 | |||
| LR | 22.3 | 12.4-39.9 | |||
| II-IV | RIC, fludarabine/ high-dose busulfan, fludarabine/treosulfan | D1 | 58.8 | 39.5-87.6 | 14.8/< .001 |
| D2 | 35.1 | 25.7-47.9 | |||
| D3 | 17.1 | 9.7-30.1 | |||
| III-IV | D1 | 47.7 | 27.5-82.5 | 19.6/< .001 | |
| D2 | 14.4 | 7.8-26.5 | |||
| D3 | 7.3 | 2.8-18.9 | |||
| II-IV | Myeloablative, fludarabine/melphalan | D1 | 80.5 | 65.2-99.3 | 11.6/.003 |
| D2 | 47.4 | 37.6-59.8 | |||
| D3 | 34.7 | 23.1-52.3 | |||
| III-IV | D1 | 73.7 | 55.1-98.5 | 12.9/.002 | |
| D2 | 31.3 | 22.2-44.2 | |||
| D3 | 22.3 | 12.4-39.9 |
| Grade . | Conditioning regimen . | SNP combinations/ group of discrepancy . | Cumulative incidence, % . | 95% CI for cumulative incidence . | χ2/P . |
|---|---|---|---|---|---|
| II-IV | RIC, fludarabine/high-dose busulfan, fludarabine/treosulfan | HR | 36.5 | 24.0-55.5 | 6.5/.039 |
| MR | 34.8 | 25.4-47.9 | |||
| LR | 17.1 | 9.7-30.1 | |||
| III-IV | HR | 23.2 | 12.6-42.8 | 4.9/.08 | |
| MR | 16.2 | 9.1-28.7 | |||
| LR | 7.3 | 2.8-18.9 | |||
| II-IV | Myeloablative, fludarabine/melphalan | HR | 69.7 | 57.5-84.7 | 12.5/.002 |
| MR | 46.1 | 35.8-59.2 | |||
| LR | 34.7 | 23.1-52.3 | |||
| III-IV | HR | 59.5 | 45.9-77.3 | 17.3/< .001 | |
| MR | 27.7 | 18.3-41.7 | |||
| LR | 22.3 | 12.4-39.9 | |||
| II-IV | RIC, fludarabine/ high-dose busulfan, fludarabine/treosulfan | D1 | 58.8 | 39.5-87.6 | 14.8/< .001 |
| D2 | 35.1 | 25.7-47.9 | |||
| D3 | 17.1 | 9.7-30.1 | |||
| III-IV | D1 | 47.7 | 27.5-82.5 | 19.6/< .001 | |
| D2 | 14.4 | 7.8-26.5 | |||
| D3 | 7.3 | 2.8-18.9 | |||
| II-IV | Myeloablative, fludarabine/melphalan | D1 | 80.5 | 65.2-99.3 | 11.6/.003 |
| D2 | 47.4 | 37.6-59.8 | |||
| D3 | 34.7 | 23.1-52.3 | |||
| III-IV | D1 | 73.7 | 55.1-98.5 | 12.9/.002 | |
| D2 | 31.3 | 22.2-44.2 | |||
| D3 | 22.3 | 12.4-39.9 |
D1: HR-LR, HR-MR recipient-donor genotype combination pairs. D2: MR-MR, MR-HR, MR-LR, HR-HR recipient-donor genotype combination pairs. D3: LR-LR, LR-HR, LR-MR recipient-donor genotype combination pairs. Significant deviations (P < .05) are marked in bold.
RIC indicates reduced-intensity conditioning.